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The lung is exposed to a vast array of inhaled antigens, particulate matter, and pollution. Cells present in the airways must therefore
be maintained in a generally suppressive phenotype so that excessive responses to nonserious irritants do not occur; these result in
bystander damage to lung architecture, influx of immune cells to the airways, and consequent impairment of gas exchange. To this
end, the resident cells of the lung, which are predominantly macrophages, are kept in a dampened state. However, on occasion the
suppression fails and these macrophages overreact to antigenic challenge, resulting in release of inflammatorymediators, induction
of death of lung epithelial cells, deposition of extracellular matrix, and development of immunopathology. In this paper, we discuss
the mechanisms behind this macrophage-mediated pathology, in the context of a number of inflammatory pulmonary disorders.
1. Pulmonary Macrophage Populations
The distinct environment of the lung, with high oxygen
tension [1] and constant exposure to inhaled antigen,
both harmful and harmless, presents challenges for the
immune cells which patrol the airways. The inhaled matter
must mostly be ignored, in order to prevent overreaction
and subsequent bystander tissue damage in response to
nonserious challenges; such a response would fill the alveoli
with immune cells and disrupt the delicate gas-exchange
process. However, immune cells must be able to respond
rapidly to a genuine threat and, once it is dealt with,
resolve any resulting inflammation and remodel any damage
to the lung tissue. This is a complex list of requirements
and so it is not surprising that on occasion the balance
between ignorance, response, and resolution tips in the
wrong direction, resulting in immunopathology.
In the noninflamed airway, very few haematopoietic cells
are present. Of the cells in the fluid from bronchoalveolar
lavage (BAL) of naive tissue, alveolar macrophages (AM)
(identified as CD11c+CD11b−MHC IIlow autofluorescent
cells) constitute >90% [2–4]. As the first cell type to
encounter inhaled antigen, AMs are superb phagocytes,
rapidly clearing bacteria from the airways [5]. They also
help to maintain the dampened immune characteristics of
the airways by producing IL-10 [6] and directly suppressing
both dendritic cells (DC) and T cells [7–9]. After infection
has resolved, they clear the cellular debris remaining [10]
and aid in the remodelling of the lung parenchyma. The
unique environment of the lung and the constraints on
AM result in these pulmonary macrophage populations
expressing diﬀerent surface molecules to those elsewhere in
the body; for example, AMs express high CD11c, owing to
the high GM-CSF and surfactant protein D levels in the
alveoli [11], which is not seen elsewhere, and which may aid
the AM in their phagocytic function.
The second and third most common cell types in the
airways (and the dominant immune cells in the lung tissue)
are DC (CD11c+ MHC IIhigh) and inflammatory monocytes
(CD11c−MHCII−CD11b+) [3]; cells of lymphoid origin are
sparse as monocyte-derived cells dominate. In addition to
the resident steady-state lung populations, monocytes move
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in rapidly after the onset of inflammation. Both resident and
immigratingmacrophages are implicated in the development
of pulmonary immunopathology.
2. Macrophages as Mediators of Lung Pathology
Macrophages are critical in the clearance of pulmonary
pathogens [5, 12, 13]. However, in the balance between
responding to dangerous inhaled pathogens and in main-
taining a healthy airway free of immune cells, macrophages
occasionally tip into immunopathology. To avoid this, AMs
are kept in check by a variety of mediators in the lung.
Surfactant proteins A and D bind to the negative regulator
SIRP-α on the AM surface [1]; its signalling induces repres-
sion of activation and of their phagocytic function. Alveolar
epithelial cells also produce IL-10 [14], which suppresses co-
stimulatory molecule expression by the AM.
The accumulation of myeloid populations in the lung is
firmly linked to the development of disease. During early
influenza infection, airway epithelial cells produce CCL2 [15]
(MCP-1), which attracts CCR2+ monocytes into the lung
tissue from the blood [3]. Monocyte numbers peak on day
5 after influenza infection as the cells upregulate CD11c and
MHC class II, before diﬀerentiating into either macrophages
or monocyte-derived DC [3]. During this influenza infec-
tion, the majority of immigrating inflammatory cells are
from CCR2+ monocytic parents [3]; mice lacking CCR2
not only have decreased accumulation of monocytes after
influenza infection but also decreased mortality and lung
damage [3, 16, 17], with CCR2−/− mice exhibiting decreased
lactate dehydrogenase (LDH, a measure of damaged and
therefore leaky epithelium) in the BAL fluid. Ablation of
CCR2 signalling also lessens lung damage in mouse models
of pulmonary fibrosis and Mycobacterium tuberculosis [18,
19].
It is, therefore, clear that monocyte-derived cell types are
critical mediators of inflammatory damage to lung tissue. In
this paper, we discuss the mechanisms behind this damage in
the context of a series of pulmonary inflammatory disorders.
3. Bacterial Infection and Cystic Fibrosis:
Inflammatory Cytokine Storm
AMs are critical for the clearance of inhaled bacte-
rial pathogens, which they achieve through phagocytosis,
reactive oxygen species production, and the secretion of
inflammatory cytokines and chemokines to attract other
immune cells to the airways. However, the clearance of these
pathogens comes at a heavy price as these inflammatory
mediators can themselves lead to bystander damage of lung
tissue.
In cystic fibrosis (CF), this inflammatory damage is a
severe problem, with 85% of deaths as a result of persistent
inflammation triggered by recurrent rounds of bacterial
infection, clearance, inflammation, and remodelling [20–
22]. AM switching from producing IL-10 to instead secreting
a range of inflammatory cytokines (including TNF, IL-1β, IL-
6, and IL-8) is well known to be key in the development of CF
lung disease [23].
A recent study investigated this inflammatory cytokine
production by AM in the response to Burkholderia cenocepa-
cia and Burkholderia multivorans, which are key pathogens
suﬀered by CF patients that initiate infections which result
in overwhelming inflammation, cell death, and sepsis [24].
B. cenocepacia can infect AM as well as lung epithelial cells
[25] and indeed both AMs of CF patients and of CFTR−/−
mice are more permissive to infection and persistence of the
bacterium, with the mouse CFTR−/− cells showing delayed
phagolysosomal clearance compared to controls [26, 27].
Infection with B. cenocepacia results in overwhelming
cytokine production by macrophages, in particular TNF
[28], IL-8 [29], and IL-1β [2, 30]. This is a result of PI3K/Akt
signalling inactivating GSK3β, a downstream repressor of
NF-κB, thus allowing enhanced NF-κB activity, and con-
sequent significantly higher cytokine production [26]. This
macrophage production of IL-1β is enhanced in the absence
of a functional CFTR channel [24] and is caspase-1 and
TLR4-dependent. It is this hyperreaction by pulmonary
macrophages which triggers the inflammatory storm and
induces pathology and severe lung damage.
4. Influenza Infection: TRAIL and Death of
Alveolar Epithelial Cells
In 2008, Lohmeyer and colleagues proposed an interesting
newmechanism by whichmacrophages contribute to pathol-
ogy during influenza infection [16]. It had been noted pre-
viously that patients with highly pathogenic influenza virus
infection suﬀered widespread destruction of the respiratory
epithelium [31, 32], but how this occurred was not clear.
Lohmeyer’s group showed that during infection of mice with
PR/8 influenza, CCR2+ monocytes which were recruited to
the lung and became exudate macrophages were mediating
this cell death [16, 33].
On moving into the lung, CCR2-recruited exudate
macrophages upregulate TRAIL (TNF-related apoptosis-
inducing ligand), with mRNA levels fourfold higher than
peripheral blood monocytes in the same infected mice
[16]. Correspondingly, although all alveolar epithelial cells
express a low level of DR5, the TRAIL receptor, it too
was upregulated following influenza infection (Figure 1).
Blockade of TRAIL on these cells resulted in lessened alveolar
epithelial cell death and alveolar leakage, and improved
survival. Interestingly, this TRAIL-induced death was seen in
the highly pathogenic PR/8 but not the milder X31 infection,
indicating this may be an additional mechanism by which
pandemic flu strains damage the lung.
Following these interesting results, a more recent paper
showed blockade of CCL2 following influenza infection led
to an increase in epithelial damage [34], with this being
explained by the reduced numbers of cells leaving the AEC
more open to infection, ascribing a protective role only to
AM, and indeed a role in repairing the influenza-infected
epithelium following clearance of the infection. Indeed, anti-
CCL2 treatment resulted in a decrease in hepatocyte growth
factor (HGF) present in the lung [34]; HGF augments
resolution and repair of damaged epithelium. In this paper,
however, the virus used was the sublethal Aichi strain,
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Figure 1: Alveolar macrophage-mediated disease in the lung. AMs are the dominant cell type in the uninfected airway. Following virus
infection (1), AMs are restrained from overreacting and inducing bystander damage to tissues by the CD200R on their surface (2) which
induces a negative signalling cascade. (3) Pandemic influenza strains induce the upregulation of TRAIL on the AM surface and of its receptor
DR5 on the alveolar epithelial cells, which leads to increased apoptosis in the epithelium and consequent morbidity. Both the presence of
TRAIL and the absence of CD200R can induce epithelial damage and spread of virus out of the alveolus (4). Bacterial infection (5) induces
AM to produce inflammatory cytokines (6), leading to activation of bystander cells and tissue damage. AMs are also triggered to produce
growth factors (7) which leads to epithelial hyperplasia, deposition of ECM and fibrosis.
supporting the theory that this AM-mediated cell death is
only a factor in highly pathogenic strains.
5. Secondary Bacterial Infections:
CD200 and CD200R
We [35] and others [36] have previously described the
role of the CD200R on macrophages in the context of
influenza infection. CD200 is expressed on airway epithelial
cells, T cells, B cells, and some DC [35, 37–40], but has
no intracellular signalling motif; its function is to bind
to CD200R on myeloid-origin cells and induce a negative
signalling cascade. AM express a high basal level of the
receptor, allowing them to maintain a strong threshold
for response in the normal lung, and prevent bystander
tissue damage in the context of inhaled, but nonpathogenic,
antigen. CD200−/− mice develop severe immune-mediated
lung damage and morbidity following influenza infection
[35] as a result of the loss of this “dampening” of the
pulmonary macrophage population (Figure 1).
More recent studies with these mice have linked the
CD200/R pathway to the development of bacterial pneumo-
nia following a primary influenza infection [41]. Secondary
bacterial infections following influenza, particularly pan-
demic strains, are common and are responsible for sudden
development of pneumonia. In the 1918 influenza pandemic,
pneumococcal cultures could be grown from the majority of
patients [42] and in the decades since then, the link between
severe influenza-related pneumonia and secondary bacterial
infections has grown stronger.
The role of macrophages and their negative regulation in
an influenza—Streptococcus pneumoniae coinfection model
was investigated [41]. In the absence of CD200R on AM,
outgrowth of S. pneumoniae, sepsis and death were reduced.
It was proposed that following an initial viral infection,
an upregulation of CD200 on pulmonary immune cells
and production of IL-10 means that the negative signals
received by both alveolar and exudate macrophages are
greatly increased. This is presumably to allow the lung a
period of grace to clear dead cells and to remodel post-
infection. However, the “immune rheostat” can swing too
far towards repression, resulting in the lung macrophage
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populations not reacting to bacterial infection as they ought,
and consequent outgrowth and sepsis [41]. As a majority of
clinical influenza cases are thought to involve a secondary
bacterial infection, this pathway is of significant therapeutic
concern.
6. IPF: Production of Arginase and
Proinflammatory Cytokines
Idiopathic pulmonary fibrosis (IPF) is a progressive intersti-
tial lung disease, which is proposed to develop as a result of
overexuberant remodelling following pulmonary epithelial
damage [43], and which is characterised by chronic inflam-
mation, alveolar epithelial hyperplasia, and deposition of
extracellular matrix leading to development of a permanent
“scar” [19, 44]. There has been much interest in the possible
role of viruses in the development of the inflammation;
in a mouse model, mice defective in IFN-γR signalling
are unable to clear murine herpesvirus infection, and the
ensuing chronic infection leads to symptoms very similar to
IPF [45, 46].
Recently, a role for macrophages has been delin-
eated in this pathological process. In a model of IPF
induced by intratracheal FITC deposition, lung damage
was lymphocyte-independent and reduced in CCR2−/− mice
[19]. Macrophages are also dominant in the γ-herpesvirus
infected mouse lung, and they localise to areas of epithelial
hyperplasia and remodelling [47]. CCL2 and CCL3 are
produced in the lung in the early stages of inflammatory
fibrotic disease [47], attracting macrophages so that they
can phagocytose debris, produce matrix metalloproteinases
(MMPs) to alter the ECM degradation or alternatively
produce ECM components themselves. These useful roles
for macrophages are a result of their alternative activation;
macrophages activated by Th2 cytokines upregulate a num-
ber of genes linked to wound healing, proliferation, and
angiogenesis, including the secretion of a number of growth
factors and of fibronectin (reviewed in [48]).
The mechanism by which macrophages are pathological
in IPF is a result of this alternative activation. Lung fibrosis
mediated by γ-herpesvirus is associated with recruitment of
macrophages to the lung, their exposure to Th2 cytokines
and subsequent alternative activation. Both the damaged
lungs and the macrophages within stained positive for
arginase 1, in both a mouse model and in patient samples
[47]. AAMs have increased arginase activity; its role in
converting arginine to ornithine, proline, and polyamine
induces proliferation of fibroblasts, collagen production and,
subsequently, the development of fibrosis [49].
In addition to arginase, macrophages are a critical factor
in the initiation of fibrosis through their production of
TNF, IL-6, IL-1β, and TGFβ and of platelet-derived growth
factor (PDGF) ([50], reviewed in [44]). These, in particular
PDGF and TGFβ, induce the proliferation of myofibroblasts,
which secrete collagen [51]. Pulmonary macrophages also
secrete MMPs, which degrade the extracellular matrix and
so attract more immune cells to the site, perpetuating the
inflammatory and remodelling cycle and exacerbating the
formation of scar tissue.
7. Summary
In the absence of infection, cautiously reactive alveolar
macrophages are the perfect guardians of the immune
response in the lung, preventing overreaction to inhaled
antigen and maintaining a generally “suppressive” environ-
ment. In addition, both alveolar and exudate macrophages
are important in the early clearance of pathogens. However,
following antigenic challenge, macrophages can tip from
protection into immunopathology, with the best features
that make them ideal to patrol the airways—cytokine and
chemokine production, killing and phagocytosis of infected
cells, clearance of debris, and remodelling of the lung—
becoming damaging. The untethering of AM constraints
and their resulting inflammatory cytokine storm in response
to bacterial and viral infection can lead to development of
epithelial cell death and consequent septic spread of bacteria
to the blood, inappropriate migration of other cell types
into the lung, clogging of the airways, deposition of ECM,
and dysregulated repair of the damaged tissue. It is for these
reasons that the constraining of AM responses during disease
remains an attractive therapeutic target.
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